Skip to main content
Clinical Trials/NCT04424160
NCT04424160CompletedNot Applicable

Effects of Intrauterine Platelet Rich Plasma (PRP) on Endometrium and Pregnancy Rates in Patients With Suboptimal Endometrium Undergoing Frozen Embryo Transfer

Acibadem University2 sites in 1 country150 target enrollmentStarted: September 15, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
150
Locations
2
Primary Endpoint
Endometrial thickness during hormone replacement therapy

Study Overview

Brief Summary

Intrauterine platelet rich plasma will be injected in the endometrial region via the vaginal route after the cessation of menstrual period. The endometrial thickness will be assessed under ultrasound and hormone replacement will be started. As the endometrial thickness reaches adequate thickness during ultrasound follow-up, embryo transfer will be performed.

Detailed Description

Intrauterine platelet rich plasma will be injected in the endometrial region via the vaginal route after the cessation of menstrual period. In the second menstrual period following the PRP injection, the endometrial thickness will be assessed under ultrasound and hormone replacement will be started. As the endometrial thickness reaches adequate thickness during ultrasound follow-up, embryo transfer will be performed. Pregnancy test results will be recorded and followed.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
20 Years to 45 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Women in whom cycle was cancelled due to an endometrial thickness <7 mm when progesterone start was planned in patients undergoing frozen embryo transfer with hormone replacement therapy
  • Women with a history of Asherman syndrome, but no obvious intrauterine adhesion in the last hysteroscopic procedure;
  • Women who have at least 2 frozen good-quality embryos.

Exclusion Criteria

  • Women with any other known cause of implantation failure, such as poor embryo quality, or congenital uterine anomalies, endometrial polyp or fibroid,
  • Previous diagnosis of any malignancy,
  • Anticoagulant use for which plasma infusion is contraindicated,

Outcomes

Primary Outcomes

Endometrial thickness during hormone replacement therapy

Time Frame: 2-10 months

To measure endometrial thickness assessed by ultrasound during hormone replacement therapy for endometrial preparation in frozen-thawed cycles

Secondary Outcomes

  • Pregnancy outcomes after frozen-thawed embryo transfer(2-10 months)

Investigators

Sponsor
Acibadem University
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Bulent Tiras

Prof.

Acibadem University

Study Sites (2)

Loading locations...

Similar Trials

Effects of Platelet Rich Plasma on... | Clinical Trial